The Role of Furosemide Stress Test in the Intensive Care Clinic
The Role of Furosemide Stress Test in Predicting Acute Kidney Injury Progression and Need for Renal Replacement Therapy in Patients Followed in the Intensive Care Clinic
Gulhane Training and Research Hospital
140 participants
Nov 1, 2024
INTERVENTIONAL
Conditions
Summary
AKI causes high mortality and morbidity, especially in critically ill patients, and prolongs the patient's stay in the intensive care unit. Due to the high morbidity and mortality associated with AKI, many researchers are studying several new biomarkers for earlier detection of AKI, determination of etiologies, and prediction of outcomes. However, the use of these new biomarkers may be limited due to reimbursement issues. In addition to the therapeutic role of furosemide in fluid balance, blood pressure control, and hypercalcemia management, Chawla et al. recommend the furosemide stress test (FST) as a tool to predict AKI progression. Designing a test that predicts the probability of AKI progression will help us make better decisions regarding the optimal timing of RRT initiation. In this study, we aimed to evaluate the feasibility of using the FST test in determining the progression of AKI in patients hospitalized in the intensive care unit and the need for RRT using the noninvasive procedure furosemide stress test.
Eligibility
Inclusion Criteria3
- Those who meet KDIGO AKI stage 1 and stage 2 criteria in the first 24 hours
- Those with sufficient fluid volume (CVP≥6 cmH20)
- Female and male patients over the age of 18 will be included in the study
Exclusion Criteria13
- Pregnant patients
- Hospitalization due to intoxication
- Liver or kidney transplant
- Glomerular filtration rate below 30 ml/min/1.73m2
- Active bleeding
- Patients with obstructive uropathy
- Patients in need of urgent RRT (K≥6.6 meq/L, pH<7.15, pulmonary edema due to fluid overload, uremic complications)
- Patients evaluated as KDIGO AKI stage 3
- Patients who have received RRT in the last 30 days
- Patients with CKD diagnosis
- Patients with pulmonary embolism
- Hypoalbuminemia≥2.5 g/dl,
- Patients receiving cephalosporin treatment will be excluded from the sample.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Furosemide will be administered intravenously in the form of a push at a dose of 1 mg/kg to furosemide-naïve patients who meet the inclusion criteria and at a dose of 1.5 mg/kg to patients exposed to furosemide.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06765031